| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6f27150911a00ed0d5afa4abbc59d255
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_929759c757d359a24539b24695d2be3c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S424-06 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6489
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22 |
| filingDate |
1989-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e093d310dd3b171b8212633e1770652
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c72d786cf8371f15785ec758db291c72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70e48f78e426b6a406ea5c9747a4c241 |
| publicationDate |
1990-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0396719-A1 |
| titleOfInvention |
FACTORS FOR REGULATING NEURITY GROWTH. |
| abstract |
Therapeutic and diagnostic use of genes and their encoded proteins (known as neurite growth regulating factors). The proteins according to the present invention include metalloproteases associated with glioblastoma cells and other malignant tumors which are at risk of forming brain metastases. The inhibitory proteins associated with myelin CNS prevent the exaggerated growth of neurites in nerve cells and in neuroblastoma cells, and can also prevent the spread of fibroblasts. These inhibition proteins include a protein whose molecular weight is 35,000 daltons and a protein whose molecular weight is 250,000 daltons, as well as their analogs, derivatives and fragments. The inhibitory proteins associated with myelin CNS can be used for the treatment of malignant tumors. The present invention also relates to antibodies to proteins associated with myelin CNS; these antibodies can be used to diagnose and treat nerve damage due to trauma, infarction and degenerative disorders of the central nervous system. In one of the specific embodiments of the present invention, the IN-1 monoclonal antibody can be used to promote the regeneration of nerve fibers over long distances in the event of spinal cord injury. The metalloproteases according to the present invention are useful for treating nerve damage and degenerative disorders of the nervous system. The present invention further relates to metalloprotease inhibitors. These inhibitors can be combined with inhibition proteins associated with CNS myelin to treat malignant tumors. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6566094-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6576441-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7932352-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6436669-B1 |
| priorityDate |
1988-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |